222 related articles for article (PubMed ID: 20012052)
1. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome.
Cefle A; Inanc M; Sayarlioglu M; Kamali S; Gul A; Ocal L; Aral O; Konice M
Rheumatol Int; 2011 Feb; 31(2):183-9. PubMed ID: 20012052
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary hypertension in systemic lupus erythematosus: an independent predictor of patient survival.
Min HK; Lee JH; Jung SM; Lee J; Kang KY; Kwok SK; Ju JH; Park KS; Park SH
Korean J Intern Med; 2015 Mar; 30(2):232-41. PubMed ID: 25750566
[TBL] [Abstract][Full Text] [Related]
3. Subclinical Pulmonary Hypertension in Childhood Systemic Lupus Erythematosus Associated with Minor Disease Manifestations.
Anuardo P; Verdier M; Gormezano NW; Ferreira GR; Leal GN; Lianza A; Ferreira JC; Pereira RM; Aikawa NE; Terreri MT; Magalhães CS; Appenzeller S; Dos Santos MC; Sachetti SB; Len CA; Pilleggi GS; Lotufo S; Bonfá E; Silva CA
Pediatr Cardiol; 2017 Feb; 38(2):234-239. PubMed ID: 27826712
[TBL] [Abstract][Full Text] [Related]
4. Systemic lupus erythematosus in Spanish males: a study of the Spanish Rheumatology Society Lupus Registry (RELESSER) cohort.
Riveros Frutos A; Casas I; Rúa-Figueroa I; López-Longo FJ; Calvo-Alén J; Galindo M; Fernández-Nebro A; Pego-Reigosa JM; Olivé Marqués A;
Lupus; 2017 Jun; 26(7):698-706. PubMed ID: 27799439
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary arterial hypertension in SLE: what do we know?
Prabu A; Gordon C
Lupus; 2013 Oct; 22(12):1274-85. PubMed ID: 24098000
[TBL] [Abstract][Full Text] [Related]
6. Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis.
Zuily S; Domingues V; Suty-Selton C; Eschwège V; Bertoletti L; Chaouat A; Chabot F; Regnault V; Horn EM; Erkan D; Wahl D
Autoimmun Rev; 2017 Jun; 16(6):576-586. PubMed ID: 28411166
[TBL] [Abstract][Full Text] [Related]
7. Subclinical right ventricle systolic dysfunction in childhood-onset systemic lupus erythematosus: insights from two-dimensional speckle-tracking echocardiography.
Leal GN; Silva KF; França CM; Lianza AC; Andrade JL; Campos LM; Bonfá E; Silva CA
Lupus; 2015 May; 24(6):613-20. PubMed ID: 25492941
[TBL] [Abstract][Full Text] [Related]
8. Raynaud's phenomenon is correlated with elevated systolic pulmonary arterial pressure in patients with systemic lupus erythematosus.
Kasparian A; Floros A; Gialafos E; Kanakis M; Tassiopoulos S; Kafasi N; Vaiopoulos G
Lupus; 2007; 16(7):505-8. PubMed ID: 17670849
[TBL] [Abstract][Full Text] [Related]
9. Arterial stiffness, antiphospholipid antibodies, and pulmonary arterial hypertension in systemic lupus erythematosus.
Lee JH; Im Cho K
J Cardiol; 2014 Dec; 64(6):450-5. PubMed ID: 24755203
[TBL] [Abstract][Full Text] [Related]
10. [Migraine in SLE: role of antiphospholipid antibodies and Raynaud's phenomenon].
Annese V; Tomietto P; Venturini P; D'Agostini S; Ferraccioli G
Reumatismo; 2006; 58(1):50-8. PubMed ID: 16639488
[TBL] [Abstract][Full Text] [Related]
11. Higher Incidence of Pulmonary Hypertension in Antiphospholipid Antibody Positive Lupus.
Ware D; Sharma V; Kalekar L; Kamble A; Mahajan A; Gokhale Y
J Assoc Physicians India; 2015 Apr; 63(4):17-20. PubMed ID: 26591164
[TBL] [Abstract][Full Text] [Related]
12. Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association?
Caccavo D; Del Porto F; Garzia P; Mitterhofer AP; Galluzzo S; Rigon A; Vadacca M; Navajas MF; Amoroso A; Afeltra A
Ann Rheum Dis; 2003 Oct; 62(10):1003-5. PubMed ID: 12972482
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of antiphospholipid antibodies in patients with overt myocardial dysfunction in systemic lupus erythematosus. A case-control study.
Gawalkar AA; Bahl A; Ahluwalia J; Sood A; Sharma A; Sharma S; Dhir V
Lupus; 2020 Oct; 29(12):1503-1508. PubMed ID: 32752919
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia.
Al Arfaj AS; Khalil N
Lupus; 2010 Dec; 19(14):1665-73. PubMed ID: 20947541
[TBL] [Abstract][Full Text] [Related]
15. Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center.
Padovan M; Castellino G; Bortoluzzi A; Caniatti L; Trotta F; Govoni M
Rheumatol Int; 2012 Jan; 32(1):129-35. PubMed ID: 20676648
[TBL] [Abstract][Full Text] [Related]
16. Antiphospholipid antibodies and non-thrombotic manifestations of systemic lupus erythematosus.
İlgen U; Yayla ME; Ateş A; Okatan İE; Yurteri EU; Torgutalp M; Keleşoğlu ABD; Turgay TM; Kınıklı G
Lupus; 2018 Apr; 27(4):665-669. PubMed ID: 29050535
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary hypertension in systemic lupus erythematosus: clinical association and survival in 18 patients.
Li EK; Tam LS
J Rheumatol; 1999 Sep; 26(9):1923-9. PubMed ID: 10493670
[TBL] [Abstract][Full Text] [Related]
18. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus.
Yoshio T; Masuyama J; Sumiya M; Minota S; Kano S
J Rheumatol; 1994 Nov; 21(11):2058-63. PubMed ID: 7869310
[TBL] [Abstract][Full Text] [Related]
19. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus.
Tanaseanu C; Tudor S; Tamsulea I; Marta D; Manea G; Moldoveanu E
Eur J Med Res; 2007 Apr; 12(4):145-51. PubMed ID: 17509958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
